Formative Pharma
Formative Pharma is a privately held Canadian specialty pharmaceutical company that develops, registers, and commercializes Health Canada-approved sterile injectable pharmaceuticals and medical devices, supplying hospitals and pharmacies across Canada (excluding Quebec) through wholesalers such as McKesson Canada and CPDN.
- Company typePrivate
- Founded2018
- HeadquartersBurlington, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Formative Pharma does
Formative Pharma Inc. is a privately held Canadian specialty pharmaceutical company founded in 2018 and headquartered in Burlington, Ontario. The company specializes in the development, registration, and commercialization of Health Canada-approved sterile injectable pharmaceuticals and medical devices for the Canadian market, excluding Quebec. Its portfolio comprises nine distinct formulations across four therapeutic categories: local anesthetics (Lidocaine Hydrochloride 1% and 2% in vial and ampoule presentations; Bupivacaine Hydrochloride in Dextrose 0.75% for spinal anesthesia), antivirals (Ganciclovir), anticoagulants (Bivalirudin), and antineoplastic agents (Fulvestrant for breast cancer; Cabazitaxel in 4.5 mL and 6 mL vial presentations for prostate cancer). Products are positioned as value-add alternatives to incumbent brand-name drugs (Xylocaine, Marcaine, Cytovene, Angiomax, Faslodex) with features including preservative-free formulations, latex-free container systems, and unit-of-use 2D barcodes with variable data and GTINs for supply-chain traceability.
The company operates a sales-led go-to-market model targeting hospitals and pharmacies across Canada, distributing through two major pharmaceutical wholesalers — McKesson Canada and the Canadian Pharmaceutical Distribution Network (CPDN) — with direct customer service and an online ordering platform for institutional buyers. Revenue is generated primarily through per-unit product sales (hardware-style model), supplemented by a co-pay assistance program that provides eligible patients with up to 20% financial support, administered through Auxilium Health. Marketing is digital-first, using the corporate website, LinkedIn, product monographs, and healthcare-professional-targeted educational content (including a co-developed video series with Infusion Excellence Consulting on elastomeric device use). The company is led by founder Lee Mangubat (President & CEO), with Lauren Barth as COO and Karen Patrick as EVP of Scientific Affairs; the executive team collectively brings 150+ years of sterile pharmaceutical experience. No institutional funding rounds, M&A activity, or AI/ML capabilities are disclosed in the available data.
Formative Pharma firmographics
Firmographics- Name
- Formative Pharma
- Legal name
- Formative Pharma Inc.
- Website
- https://formativepharma.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Formative Pharma is a privately held Canadian specialty pharmaceutical company that develops, registers, and commercializes Health Canada-approved sterile injectable pharmaceuticals and medical devices, supplying hospitals and pharmacies across Canada (excluding Quebec) through wholesalers such as McKesson Canada and CPDN.
- Ownership category
- akta.pro rank
Formative Pharma industry classification
Industry- Product category
- Specialty Pharmaceutical Injectables
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)
Keywords
Where Formative Pharma is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Formative Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Revenue generated from the sale of Health Canada approved pharmaceutical injectables and medical devices to hospitals and pharmacies across Canada. The company commercializes a portfolio of specialty products including local anesthetics, antivirals, anticoagulants, and antineoplastic agents.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Co-Pay Assistance Program - up to 20% support |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Formative Pharma product offering
Product offeringCore offering
Formative Pharma develops, registers, and commercializes Health Canada approved specialty pharmaceutical injectables and medical devices for the Canadian market. The portfolio spans local anesthetics (Lidocaine, Bupivacaine), antivirals (Ganciclovir), antineoplastic agents (Fulvestrant, Cabazitaxel), and anticoagulants (Bivalirudin), sold to hospitals and pharmacies through direct sales and wholesale distribution channels. The company also offers a Co-Pay Assistance Program providing up to 20% financial support to eligible patients on listed medications.
Product overview
Formative Pharma is a Canadian pharmaceutical company specializing in Health Canada-approved pharmaceutical injectables and medical devices. The product portfolio consists of nine distinct sterile injectable formulations: Lidocaine Hydrochloride (1% and 2%) in both vial and ampoule presentations for local anesthesia; Bupivacaine Hydrochloride in Dextrose 0.75% hyperbaric solution for spinal anesthesia; Ganciclovir antiviral powder for injection; Fulvestrant estrogen receptor antagonist pre-filled syringe for breast cancer; Bivalirudin direct thrombin inhibitor powder for injection; and Cabazitaxel antineoplastic agent (4.5 mL and 6 mL vials) for prostate cancer treatment. Products are distributed with full traceability including DINs, GTINs, and 2D barcodes with variable data. The company also operates a Co-Pay Program providing up to 20% financial assistance for eligible medications.
Differentiator
Problem solved
Functional benefit
Products and services
- Lidocaine Hydrochloride Injection USP 1% (10 mg/mL, 5 mL Vial) Local anesthetic for infiltration and nerve block procedures. Preservative-free formulation with latex-free vial stopper. Health Canada approved.
- Lidocaine Hydrochloride Injection USP 1% (10 mg/mL, 5 mL Ampoule) Local anesthetic for infiltration and nerve block procedures in ampoule presentation. Preservative-free formulation. Packaged as 25 x 5 mL ampoules per carton.
- Lidocaine Hydrochloride Injection USP 2% (20 mg/mL, 5 mL Vial) Higher concentration local anesthetic for infiltration and nerve block procedures. Preservative-free formulation with latex-free vial stopper. Brand reference: Xylocaine.
- Ganciclovir for Injection (500 mg/vial, 10 mL Vial) Antiviral sterile powder for solution for injection, indicated for the treatment of CMV (cytomegalovirus) infections. Brand reference: Cytovene. Packaged as 25 vials per carton. Features 2D barcode with variable data, GTIN, preservative-free formulation, and latex-free vial stopper.
- Fulvestrant Injection (50 mg/mL, 5 mL Pre-filled Syringe) Non-steroidal estrogen receptor antagonist for the treatment of breast cancer. Sterile solution in a pre-filled syringe. Brand reference: FASLODEX. Components in contact with drug product solution are latex-free.
- Bupivacaine Hydrochloride in Dextrose Injection USP 0.75% (7.5 mg/mL, 2 mL Ampoule) Sterile hyperbaric local anesthetic solution for spinal anesthesia. Brand reference: Marcaine. Packaged as 10 x 2 mL ampoules per carton.
- Bivalirudin for Injection (250 mg/vial, 10 mL Vial) Direct thrombin inhibitor anticoagulant for intravenous use. Sterile powder for solution. Brand reference: Angiomax. Packaged as 10 x 250 mg vials per carton.
- Cabazitaxel for Injection (10 mg/mL, 4.5 mL Vial) Antineoplastic agent for intravenous infusion used in prostate cancer treatment. Single-dose vial formulation.
- Cabazitaxel for Injection (10 mg/mL, 6 mL Vial) Antineoplastic agent for intravenous infusion used in prostate cancer treatment. Vial secured with plastic sleeve and bottom puck. Brand reference: SANDOZ.
Quantifiable outcome
- Growing portfolio of Health Canada approved pharmaceutical injectables and medical devices focused on quality of life enhancement for Canadians.
Companies that use Formative Pharma
Customer profileSegments3 records
Ideal customer profiles3 records
Formative Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Formative Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Infusion Excellence ConsultingcorePartnership for development of educational video content on elastomeric devices. Includes a two-part video series for nurses demonstrating how to effectively teach patients to independently use elastomeric devices, and a four-part video series for patients with step-by-step instructions on safe usage of elastomeric devices.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Formative Pharma competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Formative Pharma social profiles
Digital presenceFormative Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Formative Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Formative Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Formative Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Formative Pharma
What does Formative Pharma do?
Formative Pharma develops, registers, and commercializes Health Canada approved specialty pharmaceutical injectables and medical devices for the Canadian market. The portfolio spans local anesthetics (Lidocaine, Bupivacaine), antivirals (Ganciclovir), antineoplastic agents (Fulvestrant, Cabazitaxel), and anticoagulants (Bivalirudin), sold to hospitals and pharmacies through direct sales and wholesale distribution channels. The company also offers a Co-Pay Assistance Program providing up to 20% financial support to eligible patients on listed medications.
Is Formative Pharma a public or private company?
Formative Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Formative Pharma founded?
Formative Pharma was founded in 2018. It employs 11 to 50 people.
Where is Formative Pharma based?
Formative Pharma is headquartered in Burlington, Canada, in the North America region.
How does Formative Pharma make money?
One revenue line is on record: pharmaceutical Product Sales.
Does Formative Pharma have an API?
No public API is recorded for Formative Pharma.
What industry is Formative Pharma in?
Formative Pharma's product category is Specialty Pharmaceutical Injectables. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of CRAOAHAK, Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops). Its NAICS code is 325412 and its SIC code is 2834.